Human CD272 (BTLA, B and T Lymphocyte Attenuator) is a member of the Immunoglobulin superfamily and has sequence homology to PD-1 and CTLA4. It is expressed on T and B lymphocytes and other hemopoetic lineages. Engagement of this molecule by its ligand, CD270(HVEM, a TNF superfamily member) can down regulate activated T and B cell responses. CD272 levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines (1). Polymorphism of the CD272 molecule has been linked to rheumatoid arthritis (3).

Antibodies ANC6E9 and ANC5A5(cat #372-020) each bind to a distinct epitope of CD272 and are suitable as a matched pair for EIA (see attachment).

Isotype: Murine IgG1k

Immunogen: Recombinant extracellular human CD272

Specificity: Antibody from clone ANC6E9 binds to CD272 on the cell surface of human PBMC in Flow cytometry, and to recombinant CD272-muIg (cat #542-020) in EIA.

Functional Application: Antibody ANC6E9 blocks binding of Biotinylated CD270(HVEM)-muIg(cat #531-030) to CD272-muIg in EIA.

References:

1) Derre’ L, DE Speiser, et al. (2010) J Clin Invest 120(1):157-167.

2) Otsuki N, Azuma M, et al. (2006) Biochem Biophys Res Com 344(4): 1121-1127.

3) Lin SC, Chan CH, et al. (2006) J Biomed Sci 13(6): 853-860.

4) Pasero C, D Olive, et al. (2009) Curr Mol Med 9(7): 911-927.

5) Gavrieli M, KM Murphy, et al. (2006) Adv Immunol 92: 152-185.